Welcome to the Precipio Quarterly Shareholder Update Call. All participants will be in a listen-only mode. [Operator Instructions]. Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these statements are based upon our current expectations, forecasts and assumptions and are subject to significant risks and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue or the negative of these terms or other words or terms of similar meaning. Risks and uncertainties that could cause our actual results to differ materially from those set forth in any forward-looking statements include but are not limited to the matters listed under Risk Factors in our annual report on Form 10-K and for the year ended December 31, 2019, which is on file with the Securities and Exchange Commission as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov. Statements and information including forward-looking statements speak only to the date they are provided unless an earlier date is indicated and we do not undertake any obligation to publicly update any statements or information, including forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. Now, let me hand the call over to Ilan Danieli, Precipio's CEO. Please go ahead.

Thank you, Sarah, and good afternoon, everyone. I would like to thank you all for joining our Q2 2020 shareholder call. This has certainly been an unusual quarter, one where the world has changed in the way that none of us could have anticipated. Many businesses and millions of people have been hit hard by the COVID-19 pandemic. We've all had to learn how to interact and conduct business in a new environment and in a very different manner. For many, survival has been the goal during the past six months. So it is within that context, I'm delighted to share with you some incredible progress that our company has made in the second quarter of this year. During this call, I'll provide our investors with a quick overview of our company core businesses, and share the progress we're making in each of those businesses. I'll also discuss some of our plans going forward as well as, of course, address and COVID-19 initiative. But before that, for the sake of many of our new shareholders, let me begin with our company vision because that's what drives all of us. We started Precipio almost a decade ago with a vision of building a company to battle the unacceptable problem of disease misdiagnosis. We decided to focus on the scariest word in healthcare, cancer, and attempt to make an impact on patients' lives. Within cancer, we focus on blood-related cancers which according to numerous publications reaches rate of misdiagnosis as high as 25%. Over the years, we developed a platform that combines the highest quality of laboratory professionalism, advanced technologies, and academic expertise with world leading institutions. The company's dedicated focus and hard work has resulted in delivering a diagnostic accuracy rate of close to 100%. Our business is built of two…

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect. End of Q&A: